Metilfenidato Viatris

Methylphenidate hydrochloride, the active ingredient in Metilfenidato Viatris, is a central nervous system stimulant presented as an oral tablet for oral use. It is prescribed primarily for the treatment of attention deficit hyperactivity disorder and narcolepsy in children, adolescents, and adults. It is available in various dosages to allow individualized therapy.

GNH USA supplies Metilfenidato Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved documentation for each batch.

Metilfenidato Viatris, a central nervous system stimulant, is used in the management of specific neurobehavioral disorders. - Attention deficit hyperactivity disorder (children): enhances attention and reduces hyperactive behavior to support academic performance. - Attention deficit hyperactivity disorder (adults): improves focus and executive function to aid occupational tasks. - Narcolepsy: lessens excessive daytime sleepiness and reduces cataplexy episodes.

Methylphenidate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Insomnia: difficulty falling or staying asleep, leading to daytime fatigue. - Decreased appetite: reduced food intake which may cause weight loss, especially in children. - Headache: mild to moderate cranial pain that can be intermittent or persistent.

Serious or Rare Side Effects: - Cardiovascular events: chest pain, elevated blood pressure, or irregular heart rhythms that require immediate evaluation. - Psychiatric symptoms: emergence or worsening of psychosis, mania, severe anxiety, or depressive episodes. - Severe allergic reaction: rash, facial swelling, breathing difficulty, or anaphylaxis demanding urgent care.

When prescribing methylphenidate, clinicians should consider several precautionary measures to ensure safe use. - Cardiovascular assessment: evaluate blood pressure and heart rate before initiating therapy. - Psychiatric history: screen for prior psychosis, bipolar disorder, or severe anxiety. - Growth monitoring: regularly track height and weight in pediatric patients. - Substance misuse: avoid use in individuals with a history of drug abuse. - Drug interactions: review concomitant medications that affect catecholamine pathways. - Store at ambient temperature: keep tablets in the original container, protect from moisture and heat, and store below 25 °C.

Methylphenidate can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis; avoid concurrent use. - Tricyclic antidepressants: may increase cardiovascular side effects. - Antihypertensive agents: can reduce blood pressure‑lowering effect.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): may enhance serotonergic activity. - Anticonvulsants (e.g., carbamazepine): may decrease methylphenidate plasma levels. - Proton pump inhibitors: possible slight